Physician profile
Jennifer M Riggs
NPI 1295162519
$4,702.89
in general payments reported to CMS, 2019-2025
31 companies · $864 in 2025
The $864 reported for 2025 was more than what 85% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $584 · 2023: $1,595 · 2024: $1,123 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.59 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $650.74 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $493.96 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $493.93 | 2022-2025 | Verquvo, Belsomra, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $484.99 | 2021-2025 | Farxiga, Wainua |
| Amgen INC. | $382.29 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $363.39 | 2022-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $248.06 | 2024-2025 | Selectsecure, Ffrangio, Symplicity G3 |
| Abbott Laboratories | $183.77 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $160.20 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.71 | 2025 | Jardiance |
| Abiomed | $145.39 | 2023-2024 | Impella |
| Philips North America LLC | $145.18 | 2022-2024 | (Ck4) Mcot |
| Impulse Dynamics (USA) INC. | $131.87 | 2023-2025 | Optimizer, Optimizer |
| Edwards Lifesciences Corporation | $85.16 | 2021-2023 | |
| Amarin Pharma, INC. | $76.71 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $72.60 | 2024-2025 | Watchman, Cds Broad Portfolio Offering |
| Teleflex LLC | $54.83 | 2022-2024 | Turnpike |
| Esperion Therapeutics, INC. | $51.94 | 2022-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $51.39 | 2023 | Opsumit |
| Kestra Medical Technology Services, INC. | $50.24 | 2023-2024 | Assure Wcd |
| Scpharmaceuticals INC. | $34.59 | 2023-2024 | |
| Lilly USA, LLC | $30.55 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $25.08 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $22.49 | 2025 | Arexvy |
| Kowa Pharmaceuticals America, INC. | $19.11 | 2022 | |
| Pfizer INC. | $17.30 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.51 | 2025 | |
| Irhythm Technologies, INC. | $15.45 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.06 | 2023 | Edarbyclor |
| Surmodics, INC. | $12.02 | 2024 | Pounce Venous Thrombectomy System, Pounce Lp Thrombectomy, Pounce Thrombectomy System |
| Arbor Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Riggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.